Argipressin(Synonyms: 精氨加压素 Arg8-vasopressin AVP)

Argipressin;(Synonyms: 精氨加压素; Arg8-vasopressin; AVP) 纯度: 99.82%

Argipressin (Arg8-vasopressin) 可与血管精氨酸加压素受体 V1、V2 和 V3 结合,其在 A7r5 大鼠主动脉平滑肌细胞中对 V1 的 Kd 值为 1.31 nM。

Argipressinamp;;(Synonyms: 精氨加压素; Arg8-vasopressin;  AVP)

Argipressin Chemical Structure

CAS No. : 113-79-1

规格 价格 是否有货 数量
10;mM;*;1 mL in Water ¥1181 In-stock
1 mg ¥500 In-stock
5 mg ¥800 In-stock
10 mg ¥990 In-stock
25 mg ¥1200 In-stock
50 mg ¥1600 In-stock
100 mg ; 询价 ;
200 mg ; 询价 ;

* Please select Quantity before adding items.

Argipressin 相关产品

bull;相关化合物库:

  • Drug Repurposing Compound Library Plus
  • FDA-Approved Drug Library Plus
  • FDA-Approved Drug Library Mini
  • Bioactive Compound Library Plus
  • GPCR/G Protein Compound Library
  • FDA-Approved Drug Library
  • Drug Repurposing Compound Library
  • FDA Approved amp; Pharmacopeial Drug Library
  • Drug-Induced Liver Injury (DILI) Compound Library
  • Childrenrsquo;s Drug Library
  • Peptide Library

生物活性

Argipressin (Arg8-vasopressin) binds to the V1, V2, V3-vascular arginine vasopressin receptor, with a Kd value of 1.31 nM in A7r5 rat aortic smooth muscle cells for V1.

体外研究
(In Vitro)

Argipressin binds to the vascular arginine vasopressin receptor, V1, with a Kd value of 1.31 nM in A7r5 rat aortic smooth muscle cells. It also stimulates the intracellular release of calcium in A7r5 cells (EC50=5 nM)[1]. AVP-induced [Ca2+]i signals and immunized activity against S-100 in DRG cell culture. The minimum effective concentrations of Argipressin causing [Ca2+]i responses are 100 pM in non-neuronal cells in DRG culture[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

分子量

1084.23

Formula

C46H65N15O12S2

CAS 号

113-79-1

Sequence

Cys-Tyr-Phe-Gln-Asn-Cys-Pro-Arg-Gly-NH2 (Disulfide bridge: Cys1-Cys6)

Sequence Shortening

CYFQNCPRG-NH2 (Disulfide bridge: Cys1-Cys6)

中文名称

精氨加压素

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式
Powder -80deg;C 2 years
-20deg;C 1 year
In solvent -80deg;C 6 months
-20deg;C 1 month
溶解性数据
In Vitro:;

H2O : ≥ 100 mg/mL (92.23 mM)

* “≥” means soluble, but saturation unknown.

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 0.9223 mL 4.6116 mL 9.2231 mL
5 mM 0.1845 mL 0.9223 mL 1.8446 mL
10 mM 0.0922 mL 0.4612 mL 0.9223 mL

*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month。-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。

参考文献
  • [1]. Thibonnier M, et al. Multiple signaling pathways of V1-vascular vasopressin receptors of A7r5 cells. Endocrinology. 1991 Dec;129(6):2845-56.

    [2]. Moriya T, et al. Vasopressin-induced intracellular Ca²⁺ concentration responses in non-neuronal cells of the rat dorsal root ganglion. Brain Res. 2012 Nov 5;1483:1-12.

    [3]. Keun Suk Park, et al. Role of vasopressin in current anesthetic practice. Korean J Anesthesiol. 2017 Jun; 70(3): 245–257.

Z-Gly-Gly-Arg-AMC acetate

Z-Gly-Gly-Arg-AMC acetate; 纯度: 98.58%

Z-Gly-Gly-Arg-AMC acetate 是凝血素特异性的荧光底物,可用于检测 PRP 和缺乏血小板血浆中凝血酶的生成。

Z-Gly-Gly-Arg-AMC acetateamp;;

Z-Gly-Gly-Arg-AMC acetate Chemical Structure

CAS No. : 2070009-61-7

规格 价格 是否有货 数量
10;mM;*;1 mL in DMSO ¥1393 In-stock
5 mg ¥990 In-stock
10 mg ¥1400 In-stock
50 mg ¥4000 In-stock
100 mg ; 询价 ;
200 mg ; 询价 ;

* Please select Quantity before adding items.

Z-Gly-Gly-Arg-AMC acetate 相关产品

bull;相关化合物库:

  • Bioactive Compound Library Plus
  • Peptide Library

生物活性

Z-Gly-Gly-Arg-AMC acetate is a thrombin-specific fluorogenic substrate for testing of thrombin generation in PRP and platelet-poor plasma (PPP).

分子量

639.66

Formula

C30H37N7O9

CAS 号

2070009-61-7

Sequence

Z-Gly-Gly-Arg-AMC

Sequence Shortening

ZGGR-AMC

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Sealed storage, away from moisture and light

Powder -80deg;C 2 years
-20deg;C 1 year

*In solvent : -80deg;C, 6 months; -20deg;C, 1 month (sealed storage, away from moisture and light)

溶解性数据
In Vitro:;

DMSO : 500 mg/mL (781.67 mM; Need ultrasonic)

H2O : 20 mg/mL (31.27 mM; Need ultrasonic)

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 1.5633 mL 7.8167 mL 15.6333 mL
5 mM 0.3127 mL 1.5633 mL 3.1267 mL
10 mM 0.1563 mL 0.7817 mL 1.5633 mL

*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)。-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液,再依次添加助溶剂:

——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用; 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶

  • 1.

    请依序添加每种溶剂:;10% DMSO ;; 40% PEG300 ;; 5% Tween-80 ;; 45% saline

    Solubility: ≥ 4.17 mg/mL (6.52 mM); Clear solution

    此方案可获得 ≥ 4.17 mg/mL (6.52 mM,饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例,取 100 μL 41.7 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀;向上述体系中加入50 μL Tween-80,混合均匀;然后继续加入 450 μL生理盐水定容至 1 mL。

    将 0.9 g 氯化钠,完全溶解于 100 mL ddH₂O 中,得到澄清透明的生理盐水溶液

  • 2.

    请依序添加每种溶剂:;10% DMSO ;; 90% (20% SBE-β-CD in saline)

    Solubility: ≥ 4.17 mg/mL (6.52 mM); Clear solution

    此方案可获得 ≥ 4.17 mg/mL (6.52 mM,饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例,取 100 μL 41.7 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中,混合均匀。

    将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中,再用生理盐水定容至 10 mL,完全溶解,澄清透明
  • 3.

    请依序添加每种溶剂:;10% DMSO ;; 90% corn oil

    Solubility: ≥ 4.17 mg/mL (6.52 mM); Clear solution

    此方案可获得 ≥ 4.17 mg/mL (6.52 mM,饱和度未知) 的澄清溶液,此方案不适用于实验周期在半个月以上的实验。

    以 1 mL 工作液为例,取 100 μL 41.7 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中,混合均匀。

*以上所有助溶剂都可在 MCE 网站选购。
参考文献
  • [1]. Tarandovskiy ID, et al. Antiplatelet agents can promote two-peaked thrombin generation in platelet rich plasma: mechanism and possible applications. PLoS One. 2013;8(2):e55688.

    [2]. Machlus KR, et al. Effects of tissue factor, thrombomodulin and elevated clotting factor levels on thrombin generation in the calibrated automated thrombogram. Thromb Haemost. 2009 Nov;102(5):936-44.

Arg-Gly-Asp-Ser(Synonyms: RGDS peptide Fibronectin tetrapeptide)

Arg-Gly-Asp-Ser;(Synonyms: RGDS peptide; Fibronectin tetrapeptide) 纯度: 99.76%

Arg-Gly-Asp-Ser 是整联蛋白结合序列,抑制整联蛋白受体 (integrin receptor) 功能。Arg-Gly-Asp-Ser 直接并特异性地结合 pro-caspase-8,pro-caspase-9 和 pro-caspase-3,但不与 pro-caspase-1 结合。

Arg-Gly-Asp-Seramp;;(Synonyms: RGDS peptide;  Fibronectin tetrapeptide)

Arg-Gly-Asp-Ser Chemical Structure

CAS No. : 91037-65-9

规格 价格 是否有货 数量
10;mM;*;1 mL in DMSO ¥610 In-stock
10 mg ¥550 In-stock
50 mg ¥1750 In-stock
100 mg ¥3150 In-stock
200 mg ; 询价 ;
500 mg ; 询价 ;

* Please select Quantity before adding items.

Arg-Gly-Asp-Ser 相关产品

bull;相关化合物库:

  • Bioactive Compound Library Plus
  • Immunology/Inflammation Compound Library
  • Peptidomimetic Library
  • Cytoskeleton Compound Library
  • Targeted Diversity Library
  • Peptide Library

生物活性

Arg-Gly-Asp-Ser is an integrin binding sequence that inhibits integrin receptor function. Arg-Gly-Asp-Ser directly and specifically bind pro-caspase-8, pro-caspase-9 and pro-caspase-3, while it does not bind pro-caspase-1.

体外研究
(In Vitro)

The Arg-Gly-Asp-Ser-modified surface causes up-regulation of αvβ3 integrin. Attachment to the Arg-Gly-Asp-Ser-treated membrane completely abolishes apoptosis induced by staurosporine, the Ca2+·Pi ion pair, and sodium nitroprusside. Arg-Gly-Asp-Ser-dependent resistance to apoptosis is eliminated, when the activity of the phosphatidylinositol 3-kinase pathway is inhibited[1]. Arg-Gly-Asp-Ser interacts with survivin, as well as with procaspase-3, -8 and -9. Arg-Gly-Asp-Ser-peptide binding to survivin is found to be specific, at high affinity (Kd 27.5 μM) and locates at the survivin C-terminus. Arg-Gly-Asp-Ser-survivin interaction appears to play a key role, since Arg-Gly-Asp-Ser lost its anti-mitogenic effect in survivin-deprived cells with a specific siRNA[4].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究
(In Vivo)

Arg-Gly-Asp-Ser (2.5 or 5 mg/kg, 1 h before LPS) significantly inhibits LPS-induced MMP-9 activity in BAL fluid 4 h post-LPS. Arg-Gly-Asp-Ser (1, 2.5 or 5 mg/kg, i.p.) administers 1 h before LPS inhibited LPS-induced increases in TNF-α and MIP-2 levels in BAL fluid at 4 h post-LPS[2]. Arg-Gly-Asp-Ser peptide significantly reduces tumor necrosis factor (TNF)-α and macrophage inflammatory protein (MIP)-2 production, and decreases myeloperoxidase (MPO) and NF-κB activity[3].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

分子量

433.42

Formula

C15H27N7O8

CAS 号

91037-65-9

Sequence

Arg-Gly-Asp-Ser

Sequence Shortening

RGDS

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Sealed storage, away from moisture

Powder -80deg;C 2 years
-20deg;C 1 year

*In solvent : -80deg;C, 6 months; -20deg;C, 1 month (sealed storage, away from moisture)

溶解性数据
In Vitro:;

DMSO : ≥ 55 mg/mL (126.90 mM)

H2O : ≥ 25 mg/mL (57.68 mM)

* “≥” means soluble, but saturation unknown.

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 2.3072 mL 11.5362 mL 23.0723 mL
5 mM 0.4614 mL 2.3072 mL 4.6145 mL
10 mM 0.2307 mL 1.1536 mL 2.3072 mL

*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)。-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。

参考文献
  • [1]. Grigoriou V, et al. Apoptosis and survival of osteoblast-like cells are regulated by surface attachment. J Biol Chem. 2005 Jan 21;280(3):1733-9.

    [2]. Moon C, et al. Synthetic RGDS peptide attenuates lipopolysaccharide-induced pulmonary inflammation by inhibiting integrin signaled MAP kinase pathways. Respir Res. 2009 Mar 9;10:18.

    [3]. Yin X, et al. Synthetic RGDS peptide attenuated lipopolysaccharide/D-galactosamine-induced fulminant hepatic failure in mice. J Gastroenterol Hepatol. 2014 Jun;29(6):1308-15.

    [4]. Aguzzi MS, et al. Intracellular targets of RGDS peptide in melanoma cells. Mol Cancer. 2010 Apr 22;9:84.

Cell Assay
[1]

Cell death is measured using the MTT analysis. This assay is based on the ability of mitochondrial dehydrogenases to oxidize thiazolyl blue (MTT), a tetrazolium salt (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenylterazolium bromide), to an insoluble blue formazan product. The cells are incubated with the MTT reagent (120 μg/mL) at 37°C for 2 h. After the supernatant is removed, 400 μL of 0.04mol/LHCl in isopropanol is added to each well, and the optical density of the solution is read at 590 nm in an enzyme-linked immunosorbent assay plate reader. As the generation of the blue product is proportional to the dehydrogenase activity, a decrease in the absorbance at 590 nm provides a direct measurement of the number of viable cells. To determine the contribution of the PI3K pathway to inhibition of apoptosis, some cell populations are pretreated with 50 μM LY294002, a PI3K inhibitor. Following this pretreatment, cell death is determined as described above.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Administration
[2]

Mice pharyngeal aspiration is performed as described. Animals are anesthetized with a mixture of ketamine and xylazine (45 mg/kg and 8 mg/kg, i.p., respectively). Test solution (30 μL) containing LPS (1.5 mg/kg) is placed posterior in the throat and aspirated into the lungs. Control mice are administrated sterile saline (0.9% NaCl). Animals are administered with Arg-Gly-Asp-Ser or RGES peptide (1, 2.5 or 5 mg/kg, i.p.) once one hour before LPS treatment and sacrificed 4 h post-LPS. Animals are also administered Arg-Gly-Asp-Ser or RGES peptide (5 mg/kg, i.p.) once at different time points (1 h before or 2 h after LPS treatment) and sacrificed 24 h post-LPS. In addition, animals are administered with αvβ3-blocking mAbs, anti-αv, or anti-β3 (5 mg/kg, i.p.) once 1 h before and sacrificed 4 h post-LPS. Animals administered with these mAbs 2 h after LPS treatment are sacrificed 24 h post-LPS

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

参考文献
  • [1]. Grigoriou V, et al. Apoptosis and survival of osteoblast-like cells are regulated by surface attachment. J Biol Chem. 2005 Jan 21;280(3):1733-9.

    [2]. Moon C, et al. Synthetic RGDS peptide attenuates lipopolysaccharide-induced pulmonary inflammation by inhibiting integrin signaled MAP kinase pathways. Respir Res. 2009 Mar 9;10:18.

    [3]. Yin X, et al. Synthetic RGDS peptide attenuated lipopolysaccharide/D-galactosamine-induced fulminant hepatic failure in mice. J Gastroenterol Hepatol. 2014 Jun;29(6):1308-15.

    [4]. Aguzzi MS, et al. Intracellular targets of RGDS peptide in melanoma cells. Mol Cancer. 2010 Apr 22;9:84.

Gly-Arg-Gly-Asp-Ser

Gly-Arg-Gly-Asp-Ser; 纯度: 95.05%

Gly-Arg-Gly-Asp-Ser 是一种五肽,构成了糖蛋白,骨桥蛋白与细胞的结合域。

Gly-Arg-Gly-Asp-Seramp;;

Gly-Arg-Gly-Asp-Ser Chemical Structure

CAS No. : 96426-21-0

规格 价格 是否有货 数量
2 mg ¥550 In-stock
5 mg ¥1100 In-stock
10 mg ¥1650 In-stock
25 mg ¥3300 In-stock
50 mg ; 询价 ;
100 mg ; 询价 ;

* Please select Quantity before adding items.

Gly-Arg-Gly-Asp-Ser 相关产品

bull;相关化合物库:

  • Bioactive Compound Library Plus
  • Peptidomimetic Library
  • Peptide Library

生物活性

Gly-Arg-Gly-Asp-Ser is a pentapeptide that forms the cell-binding domain of a glycoprotein, osteopontin. Gly-Arg-Gly-Asp-Ser binds to integrin receptors αvβ3 and αvβ5 with estimated IC50 of ∼5 and ∼6.5 μM[1]

IC50 Target

IC50: 5 μM (αvβ3), 6.5 μM (αvβ5)[2]

体外研究
(In Vitro)

Gly-Arg-Gly-Asp-Ser binds to integrin receptors αvβ3, with IC50 of 5 μM[1]. Gly-Arg-Gly-Asp-Ser-immobilized TiO2 nanotubes enhance osteoblast-like cell (MG-63) adhesion, and significantly increased cell spreading and proliferation[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

分子量

490.47

Formula

C17H30N8O9

CAS 号

96426-21-0

Sequence

Gly-Arg-Gly-Asp-Ser

Sequence Shortening

GRGDS

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Sealed storage, away from moisture

Powder -80deg;C 2 years
-20deg;C 1 year

*In solvent : -80deg;C, 6 months; -20deg;C, 1 month (sealed storage, away from moisture)

溶解性数据
In Vitro:;

DMSO : 100 mg/mL (203.89 mM; Need ultrasonic)

H2O : 33.33 mg/mL (67.96 mM; Need ultrasonic)

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 2.0389 mL 10.1943 mL 20.3886 mL
5 mM 0.4078 mL 2.0389 mL 4.0777 mL
10 mM 0.2039 mL 1.0194 mL 2.0389 mL

*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)。-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液,再依次添加助溶剂:

——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用; 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶

  • 1.

    请依序添加每种溶剂:;10% DMSO ;; 40% PEG300 ;; 5% Tween-80 ;; 45% saline

    Solubility: ≥ 2.5 mg/mL (5.10 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (5.10 mM,饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀;向上述体系中加入50 μL Tween-80,混合均匀;然后继续加入 450 μL生理盐水定容至 1 mL。

    将 0.9 g 氯化钠,完全溶解于 100 mL ddH₂O 中,得到澄清透明的生理盐水溶液

  • 2.

    请依序添加每种溶剂:;10% DMSO ;; 90% (20% SBE-β-CD in saline)

    Solubility: ≥ 2.5 mg/mL (5.10 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (5.10 mM,饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中,混合均匀。

    将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中,再用生理盐水定容至 10 mL,完全溶解,澄清透明
  • 3.

    请依序添加每种溶剂:;10% DMSO ;; 90% corn oil

    Solubility: ≥ 2.5 mg/mL (5.10 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (5.10 mM,饱和度未知) 的澄清溶液,此方案不适用于实验周期在半个月以上的实验。

    以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中,混合均匀。

*以上所有助溶剂都可在 MCE 网站选购。
参考文献
  • [1]. Bernhagen D, et al. High-Affinity RGD-Knottin Peptide as a New Tool for Rapid Evaluation of the Binding Strength of Unlabeled RGD-Peptides to αvβ3, αvβ5, and α5β1 Integrin Receptors. Anal Chem. 2017 Jun 6;89(11):5991-5997.

    [2]. Kim GH, et al. Evaluation of Osteoblast-Like Cell Viability and Differentiation on the Gly-Arg-Gly-Asp-Ser Peptide Immobilized Titanium Dioxide Nanotube via Chemical Grafting. J Nanosci Nanotechnol. 2016 Feb;16(2):1396-9.

Lys-[Des-Arg9]Bradykinin TFA

Lys-[Des-Arg9]Bradykinin TFA; 纯度: 99.48%

Lys-[Des-Arg9]Bradykinin TFA 是一种天然存在的激肽,是一种有效且高度选择性的缓激肽 B1 受体激动剂,对人,小鼠和兔子的 B1 受体的 Ki 值为 0.12 nM,1.7 nM 和 0.23 nM。Lys-[Des-Arg9]Bradykinin TFA 对 B2 受体的抑制活性较低。

Lys-[Des-Arg9]Bradykinin TFAamp;;

Lys-[Des-Arg9]Bradykinin TFA Chemical Structure

规格 价格 是否有货 数量
10;mM;*;1 mL in DMSO ¥2520 In-stock
5 mg ¥1200 In-stock
10 mg ¥2000 In-stock
50 mg ¥5000 In-stock
100 mg ; 询价 ;
200 mg ; 询价 ;

* Please select Quantity before adding items.

Lys-[Des-Arg9]Bradykinin TFA 相关产品

bull;相关化合物库:

  • Bioactive Compound Library Plus
  • GPCR/G Protein Compound Library
  • Immunology/Inflammation Compound Library
  • Neurotransmitter Receptor Compound Library
  • Targeted Diversity Library
  • Peptide Library

生物活性

Lys-[Des-Arg9]Bradykinin TFA, a naturally occurring kinin, is a potent and highly selective bradykinin B1 receptor agonist with a Ki of 0.12 nM, 1.7 nM and 0.23 nM for human, mouse and rabbit B1 receptors, respectively. Lys-[Des-Arg9]Bradykinin TFA has low inhibitory activity on B2 receptors[1][2].

体外研究
(In Vitro)

Lys-[Des-Arg9]Bradykinin is formed by the proteolytic cleavage of bradykinin, exerts its effects through bradykinin B1 receptor (B1R)[1].
Lys-[Des-Arg9]Bradykinin (Lda-BK; 10 μM) enhances the secretion of IL-12p70 and inhibits the secretion of IL-12p40 by mature hMo-DCs. Pretreatment with Lys-[Des-Arg9]Bradykinin treatment reduces the migration of mature hMo-DCs toward medium alone, suggesting that Lys-[Des-Arg9]Bradykinin may inhibit the chemokinesis of mature hMo-DCs[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究
(In Vivo)

Lys-[Des-Arg9]Bradykinin (1 μg; intra-artenal injection; New Zealand White rabbits) treatment reduces peripheral vascular resistance in LPS-induced rabbits, but the effect is brief (T1/2 is 118-195 s)[3].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

分子量

1146.22

Formula

C52H74F3N13O13

Sequence Shortening

KRPPGFSPF

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Sealed storage, away from moisture and light

Powder -80deg;C 2 years
-20deg;C 1 year

*In solvent : -80deg;C, 6 months; -20deg;C, 1 month (sealed storage, away from moisture and light)

溶解性数据
In Vitro:;

DMSO : 110 mg/mL (95.97 mM; Need ultrasonic)

H2O : 50 mg/mL (43.62 mM; Need ultrasonic)

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 0.8724 mL 4.3622 mL 8.7243 mL
5 mM 0.1745 mL 0.8724 mL 1.7449 mL
10 mM 0.0872 mL 0.4362 mL 0.8724 mL

*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)。-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液,再依次添加助溶剂:

——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用; 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶

  • 1.

    请依序添加每种溶剂:;10% DMSO ;; 40% PEG300 ;; 5% Tween-80 ;; 45% saline

    Solubility: ≥ 2.75 mg/mL (2.40 mM); Clear solution

    此方案可获得 ≥ 2.75 mg/mL (2.40 mM,饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例,取 100 μL 27.5 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀;向上述体系中加入50 μL Tween-80,混合均匀;然后继续加入 450 μL生理盐水定容至 1 mL。

    将 0.9 g 氯化钠,完全溶解于 100 mL ddH₂O 中,得到澄清透明的生理盐水溶液

  • 2.

    请依序添加每种溶剂:;10% DMSO ;; 90% (20% SBE-β-CD in saline)

    Solubility: ≥ 2.75 mg/mL (2.40 mM); Clear solution

    此方案可获得 ≥ 2.75 mg/mL (2.40 mM,饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例,取 100 μL 27.5 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中,混合均匀。

    将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中,再用生理盐水定容至 10 mL,完全溶解,澄清透明
  • 3.

    请依序添加每种溶剂:;10% DMSO ;; 90% corn oil

    Solubility: ≥ 2.75 mg/mL (2.40 mM); Clear solution

    此方案可获得 ≥ 2.75 mg/mL (2.40 mM,饱和度未知) 的澄清溶液,此方案不适用于实验周期在半个月以上的实验。

    以 1 mL 工作液为例,取 100 μL 27.5 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中,混合均匀。

*以上所有助溶剂都可在 MCE 网站选购。
参考文献
  • [1]. Rosalind Gulliver, et al. Lys-des[Arg9]-bradykinin alters migration and production of interleukin-12 in monocyte-derived dendritic cells. Am J Respir Cell Mol Biol. 2011 Sep;45(3):542-9.

    [2]. L M Fredrik Leeb-Lundberg, et al. International union of pharmacology. XLV. Classification of the kinin receptor family: from molecular mechanisms to pathophysiological consequences. Pharmacol Rev. 2005 Mar;57(1):27-77.

    [3]. G Drapeau, et al. Hypotensive effects of Lys-des-Arg9-bradykinin and metabolically protected agonists of B1 receptors for kinins. J Pharmacol Exp Ther. 1991 Dec;259(3):997-1003.

[Des-Arg9]-Bradykinin acetate(Synonyms: [Des-Arg9]-缓激肽醋酸盐)

[Des-Arg9]-Bradykinin acetate (Synonyms: [Des-Arg9]-缓激肽醋酸盐) 纯度: 96.90%

[Des-Arg9]-Bradykinin acetate 是缓激肽 B1 受体 (Bradykinin B1 receptor) 激动剂,对 B1 受体的选择性高于 B2 受体。

[Des-Arg9]-Bradykinin acetate (Synonyms: [Des-Arg9]-缓激肽醋酸盐)

[Des-Arg9]-Bradykinin acetate Chemical Structure

CAS No. : 23827-91-0

规格 价格 是否有货 数量
5 mg ¥550 In-stock
10 mg ¥880 In-stock
25 mg ¥1900 In-stock
50 mg   询价  
100 mg   询价  

* Please select Quantity before adding items.

[Des-Arg9]-Bradykinin acetate 相关产品

相关化合物库:

  • Bioactive Compound Library Plus
  • Peptidomimetic Library
  • Peptide Library

生物活性

[Des-Arg9]-Bradykinin acetate is a Bradykinin B1 receptor agonist that displays selectivity for B1 over B2 receptors.

IC50 & Target

Bradykinin B1 receptor[1]

体外研究
(In Vitro)

[Des-Arg9]-Bradykinin acetate is a Bradykinin(B1) receptor agonist. The B2 receptor mediates the action of bradykinin (BK) and lysyl-bradykinin (Lys-BK), the first set of bioactive kinins formed in response to injury from kininogen precursors through the actions of plasma and tissue kallikreins, whereas the B1 receptor mediates the action of [Des-Arg9]-Bradykinin (des-Arg9-BK) and Lys-des-Arg Arg9-BK, the second set of bioactive kinins formed through the actions of carboxypeptidases on BK and Lys-BK, respectively[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

分子量

964.07

Formula

C46H65N11O12

CAS 号

23827-91-0

Sequence

Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe

Sequence Shortening

RPPGFSPF

中文名称

[Des-Arg9]-缓激肽醋酸盐

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Sealed storage, away from moisture

Powder -80°C 2 years
-20°C 1 year

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

溶解性数据
In Vitro: 

H2O : 100 mg/mL (103.73 mM; Need ultrasonic)

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 1.0373 mL 5.1863 mL 10.3727 mL
5 mM 0.2075 mL 1.0373 mL 2.0745 mL
10 mM 0.1037 mL 0.5186 mL 1.0373 mL

*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)。-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。

参考文献
  • [1]. Leeb-Lundberg LM, et al. International union of pharmacology. XLV. Classification of the kinin receptor family: from molecular mechanisms to pathophysiological consequences. Pharmacol Rev. 2005 Mar;57(1):27-77.

  • [1]. Leeb-Lundberg LM, et al. International union of pharmacology. XLV. Classification of the kinin receptor family: from molecular mechanisms to pathophysiological consequences. Pharmacol Rev. 2005 Mar;57(1):27-77.

Phe-Met-Arg-Phe amide trifluoroacetate

Phe-Met-Arg-Phe amide trifluoroacetate; 纯度: ge;98.0%

Phe-Met-Arg-Phe amide trifluoroacetate 是一种神经肽,在肽能神经元中激活 K+ 电流,ED50 为 23 nM,这种作用具有剂量依赖性。

Phe-Met-Arg-Phe amide trifluoroacetateamp;;

Phe-Met-Arg-Phe amide trifluoroacetate Chemical Structure

CAS No. : 159237-99-7

规格 价格 是否有货 数量
5 mg ¥950 In-stock
10 mg ¥1550 In-stock
25 mg ¥3100 In-stock
50 mg ; 询价 ;
100 mg ; 询价 ;

* Please select Quantity before adding items.

Phe-Met-Arg-Phe amide trifluoroacetate 相关产品

bull;相关化合物库:

  • Bioactive Compound Library Plus
  • Peptide Library

生物活性

Phe-Met-Arg-Phe amide trifluoroacetate is an activator of K+ current, with ED50 of 23 nM in the peptidergic caudodorsal neurons.

IC50 Target

ED50: 23 nM (K+ current)[1]

体外研究
(In Vitro)

In the molluscan central nervous system, Phe-Met-Arg-Phe amide (FMRFa) acts on K+ channels in sensory, motor-, and neuroendocrine neurones. Phe-Met-Arg-Phe amide activates a novel K+ current that is characterized by a combined voltage- and receptor-dependent gating mechanism, with both factors being necessary for opening of the channels[1]. Phe-Met-Arg-Phe amide (1 μM) significantly inhibits glucose stimulated (300 mg/dL) insulin release (p<0.005) and somatostatin release (p<0.01) from the isolated perfused pancreas. Phe-Met-Arg-Phe amide (FMRF-NH2) (1 and 10 μM) is without effect on glucagon secretion, either in low glucose (50 mg/dL), high glucose (300 mg/dL), or during arginine stimulation (5 mM)[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究
(In Vivo)

Phe-Met-Arg-Phe amide (FMRFamide) stimulates growth hormone secretion in conscious OVX rats. The presence of Phe-Met-Arg-Phe amide-like immunoreactivity in neuronal elements in the hypothalamus suggested a role for this in the hypothalamic control of the anterior pituitary function. The injection of 200 ng (313.8 picomoles) of FMRFamide (in 2 uL) produces a significantly increased plasma GH 15 min after injection. The GH-increasing effect of 400-800 ng (627-1255 picomoles) of FMRFamide is already developed after 5 min and lasted up to 30 min[3].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

分子量

826.81

Formula

C33H44F6N8O8S

CAS 号

159237-99-7

Sequence

Phe-Met-Arg-Phe-NH2

Sequence Shortening

FMRF-NH2

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Sealed storage, away from moisture

Powder -80deg;C 2 years
-20deg;C 1 year

*In solvent : -80deg;C, 6 months; -20deg;C, 1 month (sealed storage, away from moisture)

溶解性数据
In Vitro:;

DMSO : 100 mg/mL (120.95 mM; Need ultrasonic)

H2O : 20 mg/mL (24.19 mM; Need ultrasonic)

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 1.2095 mL 6.0473 mL 12.0947 mL
5 mM 0.2419 mL 1.2095 mL 2.4189 mL
10 mM 0.1209 mL 0.6047 mL 1.2095 mL

*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)。-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液,再依次添加助溶剂:

——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用; 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶

  • 1.

    请依序添加每种溶剂:;10% DMSO ;; 40% PEG300 ;; 5% Tween-80 ;; 45% saline

    Solubility: ≥ 2.5 mg/mL (3.02 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (3.02 mM,饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀;向上述体系中加入50 μL Tween-80,混合均匀;然后继续加入 450 μL生理盐水定容至 1 mL。

    将 0.9 g 氯化钠,完全溶解于 100 mL ddH₂O 中,得到澄清透明的生理盐水溶液

  • 2.

    请依序添加每种溶剂:;10% DMSO ;; 90% (20% SBE-β-CD in saline)

    Solubility: ≥ 2.5 mg/mL (3.02 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (3.02 mM,饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中,混合均匀。

    将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中,再用生理盐水定容至 10 mL,完全溶解,澄清透明
  • 3.

    请依序添加每种溶剂:;10% DMSO ;; 90% corn oil

    Solubility: ≥ 2.5 mg/mL (3.02 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (3.02 mM,饱和度未知) 的澄清溶液,此方案不适用于实验周期在半个月以上的实验。

    以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中,混合均匀。

*以上所有助溶剂都可在 MCE 网站选购。
参考文献
  • [1]. Kits KS, et al. Phe-Met-Arg-Phe-amide activates a novel voltage-dependent K+ current through a lipoxygenasepathway in molluscan neurones. J Gen Physiol. 1997 Nov;110(5):611-28.

    [2]. Sorenson RL, et al. Phe-met-arg-phe-amide (FMRF-NH2) inhibits insulin and somatostatin secretion and anti-FMRF-NH2 sera detects pancreatic polypeptide cells in the rat islet. Peptides. 1984 Jul-Aug;5(4):777-82.

    [3]. Ottlecz A, et al. Phe-Met-Arg-Phe-amide (FMRFamide) stimulated growth hormone secretion in conscious OVX rats. Neuropeptides. 1987 Feb-Mar;9(2):161-7.

(Arg)9 TFA(Synonyms: Nona-L-arginine TFA Peptide R9 TFA)

(Arg)9 TFA;(Synonyms: Nona-L-arginine TFA; Peptide R9 TFA) 纯度: 96.80%

(Arg)9 TFA (Nona-L-arginine TFA)是可渗透细胞的多肽,在谷氨酸模型实验模型中保护神经的IC50值为0.78 μM。

(Arg)9 TFAamp;;(Synonyms: Nona-L-arginine TFA; Peptide R9 TFA)

(Arg)9 TFA Chemical Structure

CAS No. : 2283335-13-5

规格 价格 是否有货 数量
1 mg ¥1300 In-stock
5 mg ¥4900 In-stock
10 mg ; 询价 ;
50 mg ; 询价 ;

* Please select Quantity before adding items.

(Arg)9 TFA 相关产品

bull;相关化合物库:

  • Drug Repurposing Compound Library Plus
  • Clinical Compound Library Plus
  • Bioactive Compound Library Plus
  • Peptide Library

生物活性

(Arg)9 TFA (Nona-L-arginine TFA), a cell-penetrating peptide, exhibits neuroprotective activity with an IC50 of 0.78 μM in the glutamic acid model.

IC50 Target

IC50: 0.78 μM (neuroprotection)[1].

体外研究
(In Vitro)

Poly-arginine (e.g. (Arg)9) and arginine-rich peptides (e.g. TAT, penetratin), which belong to a class of peptides with cell-penetrating properties are neuroprotective. (Arg)9 provides significant neuroprotection in a dose–response manner following glutamic acid exposure (IC50=0.78 μM). Following kainic acid exposure, (Arg)9 is neuroprotective, but less effective than in the glutamic acid model (IC50=0.81 μM). (Arg)9 also shows neuroprotection following in vitro ischemia (IC50=6 μM)[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究
(In Vivo)

(Arg)9) (D-isoform) is neuroprotective in rat stroke models. (Arg)9) is highly neuroprotective, with efficacy increasing with increasing arginine content, has the capacity to reduce glutamic acid-induced neuronal calcium influx and requires heparan sulfate preotoglycan-mediated endocytosis to induce a neuroprotective effect[2]. (Arg)9) (D-isoform) administered intravenously at a dose of 1000 nmol/kg 30 min after permanent middle cerebral artery occlusion (MCAO) reduces infarct volume[3].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

分子量

1537.71

Formula

C56H111N36F3O12

CAS 号

2283335-13-5

Sequence

Arg-Arg-Arg-Arg-Arg-Arg-Arg-Arg-Arg

Sequence Shortening

RRRRRRRRR

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Sealed storage, away from moisture

Powder -80deg;C 2 years
-20deg;C 1 year

*In solvent : -80deg;C, 6 months; -20deg;C, 1 month (sealed storage, away from moisture)

Solvent Solubility
In Vitro:;

H2O

Peptide Solubility and Storage Guidelines:

1.;;Calculate the length of the peptide.

2.;;Calculate the overall charge of the entire peptide according to the following table:

; Contents Assign value
Acidic amino acid Asp (D), Glu (E), and the C-terminal -COOH. -1
Basic amino acid Arg (R), Lys (K), His (H), and the N-terminal -NH2 +1
Neutral amino acid Gly (G), Ala (A), Leu (L), Ile (I), Val (V), Cys (C), Met (M), Thr (T), Ser (S), Phe (F), Tyr (Y), Trp (W), Pro (P), Asn (N), Gln (Q) 0

3.;;Recommended solution:

Overall charge of peptide Details
Negative (lt;0) 1.;;Try to dissolve the peptide in water first.
2.;;If water fails, add NH4OH (lt;50 μL).
3.;;If the peptide still does not dissolve, add DMSO (50-100 μL) to solubilize the peptide.
Positive (gt;0) 1.;;Try to dissolve the peptide in water first.
2.;;If water fails, try dissolving the peptide in a 10%-30% acetic acid solution.
3.;;If the peptide still does not dissolve, try dissolving the peptide in a small amount of DMSO.
Zero (=0) 1.;;Try to dissolve the peptide in organic solvent (acetonitrile, methanol, etc.) first.
2.;;For very hydrophobic peptides, try dissolving the peptide in a small amount of DMSO, and then dilute the solution with water to the desired concentration.
参考文献
  • [1]. Meloni BP, et al. The neuroprotective efficacy of cell-penetrating peptides TAT, penetratin, Arg-9, and Pep-1 in glutamic acid, kainic acid, and in vitro ischemia injury models using primary cortical neuronal cultures. Cell Mol Neurobiol. 2014 Mar;34(2):173-81.

    [2]. Meloni BP, et al. Poly-arginine and arginine-rich peptides are neuroprotective in stroke models. J Cereb Blood Flow Metab. 2015 Jun;35(6):993-1004.

    [3]. Milani D, et al. Poly-arginine peptides reduce infarct volume in a permanent middle cerebral artery rat strokemodel. BMC Neurosci. 2016 May 3;17(1):19.

[Arg8]-Vasotocin TFA

[Arg8]-Vasotocin TFA; 纯度: 99.87%

[Arg8]-Vasotocin (TFA) 是加压素/催产素激素家族的脊椎动物神经垂体肽。

[Arg8]-Vasotocin TFAamp;;

[Arg8]-Vasotocin TFA Chemical Structure

规格 价格 是否有货 数量
5 mg ¥1400 In-stock
10 mg ¥2400 In-stock
25 mg ¥4800 询价
50 mg ; 询价 ;
100 mg ; 询价 ;

* Please select Quantity before adding items.

生物活性

[Arg8]-Vasotocin (TFA) is a vertebrate neurohypophyseal peptide of the vasopressin/oxytocin hormone family[1].

体外研究
(In Vitro)

[Arg8]-Vasotocin occurs throughout the vertebrate phyla, being present in primitive fish, the cyclostomes, and remaining unchanged in vertebrates up to and including birds[1].

[Arg8]-Vasotocin excites neurones in the dorsal vagal complex in vitro[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

分子量

1164.24

Formula

C45H68F3N15O14S2

Sequence

Cys-Tyr-Ile-Gln-Asn-Cys-Pro-Arg-Gly-NH2 (Disulfide bridge: Cys1-Cys6)

Sequence Shortening

CYIQNCPRG-NH2 (Disulfide bridge: Cys1-Cys6)

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Sealed storage, away from moisture

Powder -80deg;C 2 years
-20deg;C 1 year

*In solvent : -80deg;C, 6 months; -20deg;C, 1 month (sealed storage, away from moisture)

溶解性数据
In Vitro:;

H2O : 50 mg/mL (42.95 mM; Need ultrasonic)

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 0.8589 mL 4.2946 mL 8.5893 mL
5 mM 0.1718 mL 0.8589 mL 1.7179 mL
10 mM 0.0859 mL 0.4295 mL 0.8589 mL

*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)。-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。

参考文献
  • [1]. Ingram CD, et al [Arg8]vasotocin excites neurones in the dorsal vagal complex in vitro: evidence for an action through novel class(es) of CNS receptors. J Neuroendocrinol. 1994 Aug;6(4):415-22.

    [2]. Mihai R, et al. The effects of [Arg8]vasotocin on the firing rate of suprachiasmatic neurons in vitro. Neuroscience. 1994 Oct;62(3):783-92.

[Des-Arg9]-Bradykinin(Synonyms: [Des-Arg9]-缓激肽)

[Des-Arg9]-Bradykinin;(Synonyms: [Des-Arg9]-缓激肽)

[Des-Arg9]-Bradykinin 是一种Bradykinin (B1) 受体激动剂,对 B1 受体选择性比B2 受体高。

[Des-Arg9]-Bradykininamp;;(Synonyms: [Des-Arg9]-缓激肽)

[Des-Arg9]-Bradykinin Chemical Structure

CAS No. : 15958-92-6

规格 是否有货
100 mg ; 询价 ;
250 mg ; 询价 ;
500 mg ; 询价 ;

* Please select Quantity before adding items.

[Des-Arg9]-Bradykinin 的其他形式现货产品:

[Des-Arg9]-Bradykinin acetate

生物活性

[Des-Arg9]-Bradykinin is a Bradykinin (B1) receptor agonist that displays selectivity for B1 over B2 receptors.

IC50 Target

Bradykinin (B1) receptor[1]

体外研究
(In Vitro)

The B2 receptor mediates the action of bradykinin (BK) and lysyl-bradykinin (Lys-BK), the first set of bioactive kinins formed in response to injury from kininogen precursors through the actions of plasma and tissue kallikreins, whereas the B1 receptor mediates the action of [Des-Arg9]-Bradykinin (des-Arg9-BK) and Lys-des-Arg Arg9-BK, the second set of bioactive kinins formed through the actions of carboxypeptidases on BK and Lys-BK, respectively[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

分子量

904.02

Formula

C44H61N11O10

CAS 号

15958-92-6

Sequence

Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe

Sequence Shortening

RPPGFSPF

中文名称

[Des-Arg9]-缓激肽

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

参考文献
  • [1]. Leeb-Lundberg LM, et al. International union of pharmacology. XLV. Classification of the kinin receptor family: from molecular mechanisms to pathophysiological consequences. Pharmacol Rev. 2005 Mar;57(1):27-77.